Business Context and Reporting Period
This Form 8-K, filed on August 31, 2023, reports events occurring on August 30, 2023, regarding First Light Acquisition Group, Inc. ("FLAG") and its proposed business combination with Calidi Biotherapeutics, Inc. ("Calidi"). Upon consummation, FLAG will merge with Calidi, change its name to Calidi Biotherapeutics, Inc., and become a wholly-owned subsidiary of the new public entity ("New Calidi").
Key Financial Metrics and Capital Commitments
The filing details several capital-raising agreements executed on August 30, 2023, to support the business combination:
- Series B Financing: A prior commitment of $25.0 million for 1,000,000 shares of Series B Convertible Preferred Stock at $25.00 per share. Sellers committed an additional approximately $1.98 million via Calidi Cure.
- Non-Redemption Agreements: Agreements with Great Point and Funicular Funds to reverse the redemption of 205,714 shares. New Calidi will pay approximately $1.08 million in cash for these non-redeemed shares upon closing.
- New Money PIPE: Wootton agreed to purchase 45,714 shares of Class A Common Stock at $5.25 per share, generating gross proceeds of approximately $240,000.
- Forward Purchase Agreements (FPAs): Agreements with Great Point, Funicular Funds, and Wootton for OTC Equity Prepaid Forward Transactions. Sellers intend to purchase up to 660,000 shares of Class A Common Stock concurrently with closing, subject to recycling shares purchased in the open market and a 9.9% ownership limitation.
The filing does not provide specific revenue, profit, cash flow, or debt figures for Calidi or FLAG within this document.
Material Changes and Agreements
On August 30, 2023, FLAG and Calidi entered into definitive agreements to secure committed capital and reduce redemption risk:
- Execution of Non-Redemption Agreements to retain approximately $1.08 million in trust funds.
- Execution of a New Money PIPE Subscription Agreement for approximately $240,000.
- Execution of Forward Purchase Agreements and corresponding FPA Funding Amount PIPE Subscription Agreements with three investors to facilitate up to 660,000 shares of stock purchases.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding the anticipated benefits of the business combination. Key risks and contingencies identified include:
- Termination Risk: The possibility that negotiations terminate or definitive agreements are not finalized.
- Financing Risk: The inability to complete PIPE investments or other financing necessary to close the transaction.
- Regulatory and Listing Risk: Changes in laws, regulatory approvals, or the ability to meet stock exchange listing standards post-combination.
- Operational Disruption: Risks that the business combination disrupts Calidi's current plans and operations.
- Market Risks: Downturns in the pharmaceutical industry, global conflicts (including the conflict in Ukraine), and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the final closing date and conditions precedent for the Business Combination.
- Confirm the total aggregate capital raised from the Series B Financing, PIPE, and Forward Purchase Agreements.
- Review the specific terms of the Forward Purchase Agreements regarding the "Recycled Shares" mechanism and the 9.9% ownership cap.
- Assess the impact of the $1.08 million cash payment to Non-Redeemers on the combined company's post-closing liquidity.
- Examine the definitive proxy statement for detailed risk factors and pro forma financial information not included in this 8-K.